en.Wedoany.com Reported - Tomato System's US subsidiary CyberMD Care (CMD) officially launched the intelligent care platform "NOVA" targeting the US healthcare market on the 11th, aiming to comprehensively expand its business network in the Medicare Advantage market.
According to Tomato System, the US Medicare and Medicare Advantage markets are undergoing transformation due to the introduction of the "CMS-HCC V28" model by the Centers for Medicare & Medicaid Services (CMS). The management model has shifted from a focus on simple diagnostic codes to a systematic management of objective data and evidence that can clinically demonstrate patients' actual disease status and health risks. Accurate documentation of patients' disease status, clear presentation of clinical evidence, and systematic maintenance of chronic disease management history have become key factors determining insurers' profitability and healthcare providers' operational efficiency.
CMD pointed out that US Independent Physician Associations (IPAs) and Medicare Advantage insurers face challenges such as fragmented patient data, complex management of HCC, RAF, HEDIS, and AWV, excessive documentation burden on medical staff, and difficulties in proving patient conditions. To address these issues, NOVA integrates dispersed remote patient monitoring (RPM) data, clinical questionnaires, pain information, annual wellness visits (AWV), and HEDIS, HCC, and RAF data into a single clinical engine. The platform includes "Q FLOW," a health questionnaire system for analyzing lifestyle habits and systemic symptoms; "P FLOW," which provides three-dimensional analysis of pain location, intensity, and patterns; and "R FLOW," which collects vital signs such as blood pressure, blood glucose, heart rate, and blood oxygen saturation.
Additionally, the platform offers 30-day unit symptom and vital sign pattern analysis, automatic risk assessment based on a clinical scoring engine, and comprehensive management functions for HCC, RAF, HEDIS, and AWV. CMD stated that NOVA integrates P FLOW, Q FLOW, R FLOW, and 30-day pattern analysis functions into a single engine, enabling it to go beyond simple RPM platforms or coding solutions and serve as a platform capable of simultaneously managing patients' clinical status and financial risks.
A CMD representative noted that while multiple solutions exist in the current US market, NOVA is a unique platform that integrates structured clinical data based on P, Q, and R, RPM vital signs, and 30-day pattern analysis functions into a single engine, offering differentiated competitiveness in terms of clinical data credibility, structural level, and usability.
CMD plans to leverage the launch of NOVA to conduct sales and marketing activities targeting Medicare Advantage insurers, IPAs, large medical groups, and Value-Based Care organizations. The CMD representative stated that with NOVA at its core, the company aims to propose a new standard for evidence-based medical data platforms in the US Medicare market and lead the digital transformation of the US healthcare market. At the same time, CMD will focus on rapidly expanding its network within the US Medicare Advantage market, further strengthening its revenue structure by increasing the platform's market share.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
